Journal Article

Artesunate as a Potent Antiviral Agent in a Patient with Late Drug-Resistant Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation

Michael Y. Shapira, Igor B. Resnick, Sunwen Chou, Avidan U. Neumann, Nell S. Lurain, Thomas Stamminger, Orit Caplan, Niveen Saleh, Thomas Efferth, Manfred Marschall and Dana G. Wolf

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 46, issue 9, pages 1455-1457
Published in print May 2008 | ISSN: 1058-4838
Published online May 2008 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/587106
Artesunate as a Potent Antiviral Agent in a Patient with Late Drug-Resistant Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7–2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9–1.9 days, indicating a highly effective block in viral replication.

Journal Article.  1835 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.